Janux Therapeutics Statistics
Total Valuation
JANX has a market cap or net worth of $2.32 billion. The enterprise value is $1.69 billion.
Market Cap | 2.32B |
Enterprise Value | 1.69B |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, after market close.
Earnings Date | Aug 6, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
JANX has 51.85 million shares outstanding. The number of shares has increased by 17.45% in one year.
Shares Outstanding | 51.85M |
Shares Change (YoY) | +17.45% |
Shares Change (QoQ) | +5.00% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 317.92 |
Forward PS | n/a |
PB Ratio | 3.53 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 231.69 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 62.09, with a Debt / Equity ratio of 0.04.
Current Ratio | 62.09 |
Quick Ratio | 61.56 |
Debt / Equity | 0.04 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -13.50% and return on invested capital (ROIC) is -10.72%.
Return on Equity (ROE) | -13.50% |
Return on Assets (ROA) | -12.40% |
Return on Capital (ROIC) | -10.72% |
Revenue Per Employee | $113,859 |
Profits Per Employee | -$868,656 |
Employee Count | 64 |
Asset Turnover | 0.02 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +252.09% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +252.09% |
50-Day Moving Average | 44.61 |
200-Day Moving Average | 27.06 |
Relative Strength Index (RSI) | 54.25 |
Average Volume (20 Days) | 733,000 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, JANX had revenue of $7.29 million and -$55.59 million in losses. Loss per share was -$1.21.
Revenue | 7.29M |
Gross Profit | 7.29M |
Operating Income | -72.86M |
Pretax Income | -55.59M |
Net Income | -55.59M |
EBITDA | -53.56M |
EBIT | -55.59M |
Loss Per Share | -$1.21 |
Balance Sheet
The company has $652.58 million in cash and $24.19 million in debt, giving a net cash position of $628.39 million or $12.12 per share.
Cash & Cash Equivalents | 652.58M |
Total Debt | 24.19M |
Net Cash | 628.39M |
Net Cash Per Share | $12.12 |
Equity (Book Value) | 655.76M |
Book Value Per Share | 12.65 |
Working Capital | 648.06M |
Cash Flow
In the last 12 months, operating cash flow was -$51.50 million and capital expenditures -$1.76 million, giving a free cash flow of -$53.26 million.
Operating Cash Flow | -51.50M |
Capital Expenditures | -1.76M |
Free Cash Flow | -53.26M |
FCF Per Share | -$1.09 |
Margins
Gross margin is 100.00%, with operating and profit margins of -999.85% and -762.92%.
Gross Margin | 100.00% |
Operating Margin | -999.85% |
Pretax Margin | -762.92% |
Profit Margin | -762.92% |
EBITDA Margin | -735.01% |
EBIT Margin | -762.92% |
FCF Margin | -730.93% |
Dividends & Yields
JANX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -17.45% |
Shareholder Yield | -17.45% |
Earnings Yield | -2.40% |
FCF Yield | -2.30% |
Analyst Forecast
The average price target for JANX is $64.63, which is 44.65% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $64.63 |
Price Target Difference | 44.65% |
Analyst Consensus | Strong Buy |
Analyst Count | 8 |
Revenue Growth Forecast (5Y) | 75.30% |
EPS Growth Forecast (5Y) | 11.70% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
JANX has an Altman Z-Score of 42.34 and a Piotroski F-Score of 3.
Altman Z-Score | 42.34 |
Piotroski F-Score | 3 |